China and Russia: Behind the Scenes of Healthcare and Biotech M&As

  • Beijing’s ‘Belt and Road’ initiative has given a substantial boost to Chinese activities in its neighboring countries, with biotech and healthcare being no exception.
  • An M&A deal can go through much more easily if a local partner supports the buyer side and helps them to understand the country’s realities.
  • The Russian healthcare market is lucrative for potential investors due to a large number of state-owned and poorly managed assets. 

In 2020, the pharma and biotech industries may not be facing the same challenges the tourism and retail sectors are experiencing. Nevertheless, the global pandemic has introduced several issues to these verticals. Swift development of supply chains, uncertainty about the capital available, rapid restructuring of demand due to COVID-caused medical needs have all influenced the M&A landscape in the field.

As this PwC report states, key players in the industry are currently using their resources for internal growth, as well as getting ready for disruptions in supply chains. While pharma deal volumes in Q2 2020 showed a small bump in volumes (from 19 M&As in Q1 2020 to 22 in Q2), their values were at their lowest since Q1 2018. Biotech deal values, meanwhile, are at their minimum since Q2 2017.

On that background, the deal scene in China and Russia is especially interesting since both countries have great ambitions in the global pharma and biotech markets. Moreover, the state plays a significant role in both of them, however, international political tensions may push Beijing and Moscow closer together. How does it look from the M&A side? The panelists of the ‘Healthcare Cross-Border M&A Between China, Israel And Russia’ webinar provided some insights on the topic.

What is Driving Chinese Biotech Investments into Russia

‘In this industry, there are a lot of learning curves’, says Carl Xiao, SVP of SPH HK Investment, pointing out at the relatively long deal processes in the healthcare industry. Recently, his company entered a $400-million M&A deal with their Russian counterparts in the sphere of monoclonal antibodies. The negotiations lasted for a year and a half. From his point of view, there are several cornerstones that define the future success of any potential deal.

The first factor is trust. It takes time to build the reputation of the company, as well as establishing connections in the industry. In terms of cross-border M&A deals, one can start building a business network from small local partners and steadily expanding it. A history of successful partnerships increases the company’s visibility in the industry, Carl adds.

Another reason fueling Chinese M&A deals in this market is Beijing’s ‘Belt and Road’ initiative. This global infrastructure development strategy, which was adopted by the Chinese government in 2013, aims to invest in nearly 70 countries and promote regional connectivity. The companies, either private or state-owned, act in line with these plans and receive government support. ‘This is a very good action plan that helps to bring you overseas and find new partners, other than Western countries like the U.S. or EU members. Russia is within our scope, and a good choice for investments in the pharmaceutical industry,’ the panelist explains.

The biotech industry in Russia is also lucrative to Chinese investors due to its significantly lower entry prices in comparison to the ‘high-end’ European or American ones. Xiao also points out that the quality of the workforce in Russia is more than satisfactory. That’s crucial for the biotech industry which relies heavily on well-educated specialists and researchers.

Russian Market and its Peculiarities

‘If you want to enter the Russian market, you should first of all go to the local authorities and talk to them,’ says Dmitry Sidorov, Horizons Country Partner in Russia. He also recommends finding a local partner who can help establish a dialogue with the local authorities and give some useful hints and insights.

‘As a part of its Soviet legacy, the major player in the Russian healthcare market is the state.

Local authorities, being de-facto branches of the government, are the main regulators and competitors all in one.’ Dmitry recommends that investors look first for assets that are being used inappropriately, i.e. those which are not being managed effectively.

The choice is broad, he adds, as many state-controlled factories, clinics, labs, and MedTech companies are showing poor results. The reason is simple, the government-appointed management often doesn’t have a business approach. So, Sidorov adds, the best way for them is to sell those assets to professionals who can bring investment, technologies, and new partners. 

Dmitry gives an example of a typical situation in the Russian healthcare industry. His company assisted in an M&A deal in which a foreign investor bought a pharmaceutical factory in Russia. ‘The premises were in horrible condition since it wasn’t the owner’s main business activity,’ he explains. After the deal, the buyer renovated the factory and brought new technologies and specialists to the production facilities. Thanks to that, the company has grown into a successful player in the internal market, even winning government contracts.

Another way to enter the Russian market, Sidorov adds, is via public-private partnerships. The government has plenty of poorly managed assets in the biotech sphere, to which an investor can bring business expertise, as well as advanced technologies.

Large infrastructural projects, promoted by the government, can also serve as an entry point, like the Skolkovo innovation center where a huge healthcare/biotech cluster is being built. There, several clinics by companies from China, Israel, South Korea, and the US should emerge. The state supports such activities by creating special rules for international clusters, making their creation and operation easier, Dmitry says.

Other Insights

See More
Portugal
Porto, Portugal
Legal

Legal Frameworks for Turbulent Times: Cases of Distressed Investments in Portugal

Are there ways to prevent the wave of insolvencies expected in 2021?

See More
USA
M&A

Geopolitics and M&A: Power Play in the Turbulent World. An Interview with Klisman Murati

How do geopolitics define the long-term strategies of states, and impact the economic actors?

See More
Portugal
M&A

Distressed Investments in Portugal: An Economic and Legal Outlook

The number of insolvencies in Portugal is rising and businesses are facing uncertainty in terms of future financing.

See More
USA
Hong Kong harbor
M&A

China’s Gordian Knot of Geopolitics: Regional Expansion or Global Ambitions?

Though Beijing is being careful with international politics, in an economic scene it is more active.

See More
USA
Investment

The US vs. China: How their Geopolitical Game is Affecting M&As

Beijing remains cautious in terms of restrictive measures against the US in response.

See More
Israel
Healthcare

Changing Landscapes in Chinese, Russian, and Israeli Healthcare Investments 

The healthcare and life sciences branches seem to be struggling with the new challenges.

See More
Australia
M&A

Four Human Capital Factors to Consider during an M&A Deal

Without the proper management of human resources, the majority of M&A deals are bound to fail.

See More
Australia
M&A

Extracting Commercial Benefit from Data: Lessons for M&As

Data can be applied and bring value at various stages of the M&A process.

See More
Brazil
Legal

LGPD in Brazil: How the New Data Protection Law is impacting Businesses and Deals

Here are some useful hints and recommendations by experts in the field

See More
China
Investment

M&A Regulatory Updates in China and Abroad 

How can tightening regulations impact the M&A situation in the Asia-Pacific region?

Speakers of this event

See More
China

Carl Xiao

SVP of SPH HK Investment, Assistant GM of SPH-BIOCAD (HK) Limited
See More
Israel

Oren Gez

Founder of Eight Bridges Consulting
See More
China

Alvin Syh

CEO of Anrich Capital, CEO of BC Asset Management
See More
Russia

Dmitry Sidorov

Horizons Country Partner – Russia, Head of the Corporate and International Department CPO Group LLC
See More
China

Ruilin Zhao, Ph.D

Partner at CD Capital
See More
Russia

Aleksandr Lobakov

Managing Partner in Novus Capital
See More
China

John Yuan

Head of M&A Community China

Get In Touch

Our team is happy to answer your questions. Fill out this form and we will get in touch with you.